LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

11.64 -2.51

Buy Sell

Overview

Share price change

24h

Current

Min

11.22

Max

11.84

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.506 49.701
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+66.81% upside

Market Stats
By TradingEconomics
Market Cap	2.1B
Previous open	14.15
Previous close	11.64

News Sentiment

By Acuity

10%

90%

8 / 345 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 maj 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 maj 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 maj 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 maj 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 maj 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 maj 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 maj 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 maj 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 maj 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 maj 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 maj 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 maj 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 maj 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 maj 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 maj 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 maj 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 maj 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 maj 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 maj 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 maj 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 maj 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 maj 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

66.81% upside

12 Months Forecast

Average 20 USD 66.81%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Sentiment

By Acuity

8 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.